In the video below, Fool health care bureau chief Brenton Flynn talks about AbbVie with a focus on a few areas that investors should watch over the near term.
The first is Humira, which made up half of sales in 2012 and delivered an even higher percentage of profits. It will continue to be a key element of AbbVie's revenue growth. International growth is also worth keeping an eye on, as is AbbVie's pipeline. Humira is expected to face challenges as it loses patent protection in 2016, so knowing what new drugs the company will be selling is a very important development.
If you want more details on AbbVie, The Fool's brand new premium report on the company answers the high-profile questions that AbbVie investors are asking. Simply click here now to claim your copy today.